Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADAC's (US) molecular coincidence detection (MCD) nears market

This article was originally published in Clinica

Executive Summary

ADAC (US) expects to complete multicentre clinical trials of its molecular coincidence detection (MCD) system next year. The technology, which enables combined PET and SPECT imaging on a single dual-function system, provides improved diagnostic imaging and reduces the cost of patient care, says ADAC. The MCD system will be added to the company's Vertex Epic and Solus Epic nuclear medicine imaging systems.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel